Elgohary et al. reported high TRPS1 and moderate SOX10 expression in triple-negative breast cancer (TNBC). While these findings suggest potential diagnostic value, the absence of non-breast controls, variation in positivity thresholds, and exclusion of small biopsy and neoadjuvant-treated cases limit applicability in metastatic settings. Broader, multi-tumor validation—benchmarked against established marker panels—is needed before routine use in TNBC diagnosis.